Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase development, and five preclinical development programs. The company s approved product is MuGard TM for the management of oral mucositis a common and debilitating side effect of many cancer therapies for which marketing authorization has been allowed by the FDA. Access ProLindac TM , a polymer linked platinum cancer drug is in Phase clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company s preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian Prodrax, a non toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company s Cobalamin TM oral drug delivery technology.
Quote | Abeona Therapeutics Inc. (NASDAQ:ABEO)
Last: | $5 |
---|---|
Change Percent: | 0.0% |
Open: | $5.11 |
Close: | $5 |
High: | $5.33 |
Low: | $4.97 |
Volume: | 170,107 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Abeona Therapeutics Inc. (NASDAQ:ABEO)
2024-07-12 16:59:26 ET Summary Abeona Therapeutics Inc.'s BLA resubmission of Pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa is expected 2nd half of 2024. If Pz-cel is approved by the FDA, the company believes that it could reach peak U.S. sal...
2024-07-11 11:05:27 ET More on Abeona Therapeutics Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost Abeona Therapeutics files for $300M securities offering ...
Message Board Posts | Abeona Therapeutics Inc. (NASDAQ:ABEO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ABEO News Article - Abeona Therapeutics Announces Update on AAV Ophthalmology Program | whytestocks | investorshangout | 03/14/2023 12:21:07 PM |
whytestocks: $ABEO News Article - PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week | whytestocks | investorshangout | 11/21/2022 6:35:49 PM |
You gots me CONFUSED, Young Lady!! YES, I | Invest-in-America | investorshub | 10/12/2022 2:34:13 PM |
you already posted there silly, so i replied | gail | investorshub | 10/12/2022 2:26:24 PM |
O.K., I'll take a look at THAT one | Invest-in-America | investorshub | 10/12/2022 2:24:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...